{"address1": "60 Leveroni Court", "city": "Novato", "state": "CA", "zip": "94949", "country": "United States", "phone": "415 483 8800", "website": "https://www.ultragenyx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.", "fullTimeEmployees": 1294, "companyOfficers": [{"maxAge": 1, "name": "Dr. Emil D. Kakkis M.D., Ph.D.", "age": 64, "title": "Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1627576, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Horn", "age": 45, "title": "Executive VP of Corporate Strategy & CFO", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 947770, "exercisedValue": 0, "unexercisedValue": 261805}, {"maxAge": 1, "name": "Mr. Theodore A. Huizenga", "age": 53, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alison  Skrinar", "age": 54, "title": "Vice President of Clinical Outcomes Research and Evaluation", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Paul  Wickman J.D., Ph.D.", "title": "Vice President of Intellectual Property", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Arjun  Natesan Ph.D.", "title": "Vice President of Translational Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Samuel C. Wadsworth Ph.D.", "age": 76, "title": "Chief Scientific Officer of Ultragenyx Gene Therapy", "yearBorn": 1948, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua  Higa", "title": "Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wenchi  Liu", "title": "Corporate Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 1, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 36.21, "open": 36.06, "dayLow": 33.69, "dayHigh": 36.06, "regularMarketPreviousClose": 36.21, "regularMarketOpen": 36.06, "regularMarketDayLow": 33.69, "regularMarketDayHigh": 36.06, "payoutRatio": 0.0, "beta": 0.668, "forwardPE": -6.622309, "volume": 992732, "regularMarketVolume": 992732, "averageVolume": 815550, "averageVolume10days": 772990, "averageDailyVolume10Day": 772990, "bid": 32.32, "ask": 36.49, "bidSize": 1, "askSize": 1, "marketCap": 3177565696, "fiftyTwoWeekLow": 33.69, "fiftyTwoWeekHigh": 60.37, "priceToSalesTrailing12Months": 5.6718946, "fiftyDayAverage": 41.3886, "twoHundredDayAverage": 47.0226, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3437223168, "profitMargins": -1.01598, "floatShares": 89139635, "sharesOutstanding": 93899696, "sharesShort": 4813611, "sharesShortPriorMonth": 4284000, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.051999997, "heldPercentInsiders": 0.03454, "heldPercentInstitutions": 0.96805, "shortRatio": 6.08, "shortPercentOfFloat": 0.059699997, "impliedSharesOutstanding": 96640704, "bookValue": 2.76, "priceToBook": 12.26087, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -569182976, "trailingEps": -6.29, "forwardEps": -5.11, "enterpriseToRevenue": 6.135, "enterpriseToEbitda": -6.869, "52WeekChange": -0.28122348, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 33.84, "targetHighPrice": 136.0, "targetLowPrice": 47.0, "targetMeanPrice": 90.21053, "targetMedianPrice": 86.0, "recommendationMean": 1.47368, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 610025024, "totalCashPerShare": 6.595, "ebitda": -500430016, "totalDebt": 910009984, "quickRatio": 2.132, "currentRatio": 2.374, "totalRevenue": 560230016, "debtToEquity": 346.939, "revenuePerShare": 6.188, "returnOnAssets": -0.22373, "returnOnEquity": -2.11706, "grossProfits": -214363008, "freeCashflow": -207489744, "operatingCashflow": -414188000, "revenueGrowth": 0.294, "grossMargins": -0.38263, "ebitdaMargins": -0.89325994, "operatingMargins": -0.74163, "financialCurrency": "USD", "symbol": "RARE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -6.5451503, "regularMarketPrice": 33.84, "marketState": "PRE", "shortName": "Ultragenyx Pharmaceutical Inc.", "longName": "Ultragenyx Pharmaceutical Inc.", "fiftyDayAverageChange": -7.5485992, "fiftyDayAverageChangePercent": -0.18238354, "twoHundredDayAverageChange": -13.182598, "twoHundredDayAverageChangePercent": -0.280346, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391178600000, "preMarketChange": -0.72999954, "preMarketChangePercent": -2.1572092, "preMarketPrice": 33.11, "regularMarketChange": -2.369999, "regularMarketDayRange": "33.69 - 36.06", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 815550, "fiftyTwoWeekLowChange": 0.15000153, "fiftyTwoWeekLowChangePercent": 0.004452405, "fiftyTwoWeekRange": "33.69 - 60.37", "fiftyTwoWeekHighChange": -26.529999, "fiftyTwoWeekHighChangePercent": -0.43945667, "fiftyTwoWeekChangePercent": -28.122347, "earningsTimestamp": 1736715660, "earningsTimestampStart": 1746010740, "earningsTimestampEnd": 1746446400, "earningsCallTimestampStart": 1739484000, "earningsCallTimestampEnd": 1739484000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.29, "epsForward": -5.11, "epsCurrentYear": -5.355, "priceEpsCurrentYear": -6.319328, "corporateActions": [], "preMarketTime": 1743591009, "regularMarketTime": 1743537600, "exchange": "NMS", "messageBoardId": "finmb_117471985", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Ultragenyx Pharmaceutical", "trailingPegRatio": null}